Literature DB >> 8369987

Serum bone Gla protein as a marker of bone turnover in acromegaly.

M Marazuela1, B Astigarraga, M J Tabuenca, J Estrada, F Marín, T Lucas.   

Abstract

Serum bone Gla protein, a sensitive and specific marker of bone turnover, was measured in 35 acromegalic patients (14 untreated, 8 clinically active, and 13 cured) and 21 controls. We also examined 10 acromegalic patients before and after transsphenoidal surgery. Untreated and clinically active acromegalic patients had significantly higher serum bone Gla protein concentrations than the control subjects. Other nonspecific biochemical markers of bone metabolism, such as urinary hydroxyproline and urinary calcium, were also present in significantly greater amounts in active acromegalic patients. After treatment, a significant decrease in levels was observed, with return to control levels. In acromegalic patients, positive correlations were found among serum bone Gla protein and serum growth hormone and serum insulin-like growth factor I levels, as well as among levels of insulin-like growth factor I and serum phosphorus, serum alkaline phosphatase, and urinary hydroxyproline. These results suggest that serum bone Gla protein is a sensitive marker of the action of growth hormone in bone metabolism in acromegaly, a role that is probably mediated by insulin-like growth factor I.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8369987     DOI: 10.1007/bf00571329

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  21 in total

1.  Calcium absorption and excretion in the gut in acromegaly.

Authors:  G Sigurdsson; V Nunziata; M Reiner; A Nadarajah; G F Joplin
Journal:  Clin Endocrinol (Oxf)       Date:  1973-07       Impact factor: 3.478

2.  Routine assay of total urinary hydroxyproline based on resin-catalysed hydrolysis.

Authors:  B C Goverde; F J Veenkamp
Journal:  Clin Chim Acta       Date:  1972-10       Impact factor: 3.786

3.  The nature of the metabolic bone disorder in acromegaly.

Authors:  B L Riggs; R V Randall; H W Wahner; J Jowsey; P J Kelly; M Singh
Journal:  J Clin Endocrinol Metab       Date:  1972-06       Impact factor: 5.958

4.  Urinary hydroxyproline excretion in acromegaly.

Authors:  J Halse; J O Gordeladze
Journal:  Acta Endocrinol (Copenh)       Date:  1978-11

5.  Total and non-dialyzable urinary hydroxyproline in acromegalics and control subjects.

Authors:  J Halse; J O Gordeladze
Journal:  Acta Endocrinol (Copenh)       Date:  1981-04

6.  Iliac crest bone mass and remodelling in acromegaly.

Authors:  J Halse; F Melsen; L Mosekilde
Journal:  Acta Endocrinol (Copenh)       Date:  1981-05

7.  Effects of growth hormone (GH) on plasma bone Gla protein in GH-deficient adults.

Authors:  J S Johansen; S A Pedersen; J O Jørgensen; B J Riis; C Christiansen; J S Christiansen; N E Skakkebaek
Journal:  J Clin Endocrinol Metab       Date:  1990-04       Impact factor: 5.958

8.  Clinical evaluation of bone turnover by serum osteocalcin measurements in a hospital setting.

Authors:  D M Slovik; C M Gundberg; R M Neer; J B Lian
Journal:  J Clin Endocrinol Metab       Date:  1984-08       Impact factor: 5.958

9.  Concurrent assays of circulating bone Gla-protein and bone alkaline phosphatase: effects of sex, age, and metabolic bone disease.

Authors:  R J Duda; J F O'Brien; J A Katzmann; J M Peterson; K G Mann; B L Riggs
Journal:  J Clin Endocrinol Metab       Date:  1988-05       Impact factor: 5.958

10.  Serum bone Gla protein: a potential marker of growth hormone (GH) deficiency and the response to GH therapy.

Authors:  J S Johansen; S B Jensen; B J Riis; L Rasmussen; M Zachmann; C Christiansen
Journal:  J Clin Endocrinol Metab       Date:  1990-07       Impact factor: 5.958

View more
  8 in total

1.  Bone mineral density and turnover in patients with acromegaly in relation to sex, disease activity, and gonadal function.

Authors:  Marek Bolanowski; Jacek Daroszewski; Marek Medraś; Beata Zadrozna-Sliwka
Journal:  J Bone Miner Metab       Date:  2006       Impact factor: 2.626

Review 2.  Determinants of skeletal fragility in acromegaly: a systematic review and meta-analysis.

Authors:  Cláudia Ribeiro de Moura; Sara Campos Lopes; Ana Margarida Monteiro
Journal:  Pituitary       Date:  2022-07-22       Impact factor: 3.599

3.  Long-term effects of octreotide on markers of bone metabolism in acromegaly: evidence of increased serum parathormone concentrations.

Authors:  P Legovini; E De Menis; F Breda; D Billeci; A Carteri; P Pavan; N Conte
Journal:  J Endocrinol Invest       Date:  1997-09       Impact factor: 4.256

4.  Alterations in body composition in acromegaly.

Authors:  Laurence Katznelson
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

Review 5.  Growth hormone, insulin-like growth factors, and the skeleton.

Authors:  Andrea Giustina; Gherardo Mazziotti; Ernesto Canalis
Journal:  Endocr Rev       Date:  2008-04-24       Impact factor: 19.871

Review 6.  Effects of GH/IGF axis on bone and cartilage.

Authors:  Manisha Dixit; Sher Bahadur Poudel; Shoshana Yakar
Journal:  Mol Cell Endocrinol       Date:  2020-10-14       Impact factor: 4.102

7.  Trabecular Bone Score and Osteoprotegerin as Useful Tools in the Assessment of Bone Deterioration in Acromegaly.

Authors:  Aleksandra Jawiarczyk-Przybyłowska; Jowita Halupczok-Żyła; Joanna Syrycka; Agnieszka Zembska; Justyna Kuliczkowska-Płaksej; Marek Bolanowski
Journal:  Front Endocrinol (Lausanne)       Date:  2022-04-21       Impact factor: 6.055

Review 8.  Effect of GH/IGF-1 on Bone Metabolism and Osteoporsosis.

Authors:  Vittorio Locatelli; Vittorio E Bianchi
Journal:  Int J Endocrinol       Date:  2014-07-23       Impact factor: 3.257

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.